Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: The benefits and threats of research partnerships with industry. | Available online http content 9 4 309 Commentary The benefits and threats of research partnerships with industry Gordon DuVal University of Toronto Joint Centre for Bioethics Toronto Canada Corresponding author Gordon DuVal Published online 26 April 2005 This article is online at http content 9 4 309 2005 BioMed Central Ltd Critical Care 2005 9 309-310 DOI cc3539 During the past two decades the involvement of nonacademic sponsors of biomedical research particularly clinical trial research has increased exponentially. It is estimated that between 1980 and 2003 the overall research and development expenditure by US pharmaceutical companies increased from 2 billion to 33 billion 1 . The sources of funding for biomedical research have also shifted significantly towards industry. By 2002 70 of funding for clinical trials came from industry 2 . The involvement of industry partners in research has undoubted benefits. Drug development is extraordinarily expensive and government and other non-commercial sources of research funding have generally not been able to or willing to underwrite the enormous sums necessary to develop and test the medications and devices that have made remarkable improvements in the lives of so many. But partnership with industrial sponsors of research also carries potential threats both to human subject protection and to research integrity. Because such research may result in financial or other rewards for researchers and institutions commercially sponsored research may taint individual or institutional judgment concerning important aspects of the conduct of research. To the extent that researchers have a financial interest in the success of the research such as an equity interest in the sponsor or if the researcher has come to rely upon the sponsor for research funding or for personal income the researcher has financial interests that substantially align with those of the sponsor that is for
